Relay Therapeutics provides update on lirafugratinib

Updated FGFR2 fusion tumor agnostic data, which have generally stayed consistent with the October 2023 disclosure, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 23-25, 2024; The company met with the FDA regarding the lirafugratinib regulatory path. The FDA suggested that the company first file a new drug application in cholangiocarcinoma, followed by a tumor agnostic supplemental NDA for FGFR2 fusions with data from more patients and more follow up; The company plans to seek a global commercialization partner for lirafugratinib in order to maintain focus on the remainder of the portfolio